Neuronal vulnerability in Parkinson's disease

Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 Lim, 2009, Overview of the extranigral aspects of Parkinson disease, Arch Neurol, 66, 167, 10.1001/archneurol.2008.561 Double, 2010, Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?, Prog Neurobiol, 92, 316, 10.1016/j.pneurobio.2010.06.001 Marsden, 1961, Pigmentation in the nucleus substantia nigre of mammals, J Anat, 95, 256 Fedorow, 2005, Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease, Prog Neurobiol, 75, 109, 10.1016/j.pneurobio.2005.02.001 Fedorow, 2006, Evidence for specific phases in the development of human neuromelanin, Neurobiol Aging, 27, 506, 10.1016/j.neurobiolaging.2005.02.015 Halliday, 2005, a-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease, Brain, 128, 2654, 10.1093/brain/awh584 Li, 2005, Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells, J Neurochem, 95, 599, 10.1111/j.1471-4159.2005.03404.x Bohic, 2008, Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy, Anal Chem, 80, 9557, 10.1021/ac801817k Kastner, 1992, Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?, J Neurochem, 59, 1080, 10.1111/j.1471-4159.1992.tb08350.x Fasano, 2006, Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies, J Neural Transm, 113, 769, 10.1007/s00702-005-0448-4 Gründemann, 2011, UV-laser microdissection and mRNA expression analysis of individual neurons from postmortem Parkinson's disease brains, Methods Mol Biol, 755, 363, 10.1007/978-1-61779-163-5_30 Sian-Hülsmann, 2011, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease, J Neurochem, 118, 939, 10.1111/j.1471-4159.2010.07132.x Shamoto-Nagai, 2006, Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome, J Neural Transm, 113, 633, 10.1007/s00702-005-0410-5 Oakley, 2007, Individual dopaminergic neurons show raised iron levels in Parkinson's disease, Neurology, 68, 1820, 10.1212/01.wnl.0000262033.01945.9a Orr, 2002, An inflammatory review of Parkinson's disease, Prog Neurobiol, 68, 325, 10.1016/S0301-0082(02)00127-2 He, 2003, Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys, Free Radie Biol Med, 35, 540, 10.1016/S0891-5849(03)00385-X Friedman, 2009, Iron as a cause of Parkinson disease – a myth or a well established hypothesis?, Parkinsonism Relat Disord, 15, S212, 10.1016/S1353-8020(09)70817-X Bohic, 2009, Metallomics of neuromelanin in Parkinsonian syndromes, Parkinsonism Relat Disord, 15, S161, 10.1016/S1353-8020(09)70616-9 Whitton, 2010, Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease, Curr Opin Investig Drugs, 11, 788